PRINCETON, N.J. and SUZHOU, CHINA, February 24, 2026 -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced that members of its senior leadership team will participate in the 36th Annual Oppenheimer Healthcare Life Sciences Conference February 25-26, 2026.

36th Annual Oppenheimer Healthcare Life Sciences Conference

Format: Virtual presentation and one-on-one investor meetings
Presentation Date and Time: February 26, 2026, 12:00pm Eastern Time

Attendees:  

· Dr. Xueming Qian, Founder, Chairman and CEO

· Mr. Weiwei Liang, SVP, Business Development and Corporate Strategy; Acting CFO

· Mr. Tyler Marciniak, SVP, Capital Markets, Investor Relations & Corporate Communications

During the conference, management will discuss with investors its strategic efforts for 2026 and provide updates on its ongoing business development and operational excellence initiatives.

About Transcenta Therapeutics

Transcenta (HKEX: 06628) is a global clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in China, U.S. and Europe. Transcenta is developing a diverse pipeline of more than a dozen novel biologic therapies for oncology and selected non-oncology indications including bone and kidney disorders.

For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. For inquiries regarding Business Development opportunities, please contact us at bd@transcenta.com